Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Guardant Health, Inc. - Common Stock (NQ:GH)

65.46 -2.01 (-2.98%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Guardant Health, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Guardant Health Receives Regulatory Approval in Japan for Guardant360® CDx as Companion Diagnostic to ENHERTU® for Treatment of Non-Small Cell Lung Cancer Patients with HER2 Mutations
From Guardant Health, Inc.
Via Business Wire
Guardant Health Provides Update on COBRA Study, Restates Confidence in MRD Test
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Host Investor Day on September 7, 2023
From Guardant Health, Inc.
Via Business Wire
Guardant Health Reports Second Quarter 2023 Financial Results and Increases Revenue Guidance
From Guardant Health, Inc.
Via Business Wire
Guardant resolves pending litigation with Illumina and enters into new agreement to advance long-term commercial partnership and cancer research
From Guardant Health, Inc.
Via Business Wire
Guardant Health receives first commercial payor coverage for Guardant Reveal™ test from Blue Cross and Blue Shield of Louisiana
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Report Second Quarter 2023 Financial Results on August 3, 2023
From Guardant Health, Inc.
Via Business Wire
Guardant Health announces reimbursement approval of Guardant360® CDx liquid biopsy test in Japan
From Guardant Health, Inc.
Via Business Wire
Guardant Health to present 17 scientific abstracts highlighting contribution of its blood tests and real-world data to advances in precision oncology and cancer screening at 2023 ASCO annual meeting
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Participate in Upcoming June Investor Conferences
From Guardant Health, Inc.
Via Business Wire
Guardant Health Announces Pricing of Upsized Public Offering of Common Stock
From Guardant Health, Inc.
Via Business Wire
Guardant Health Announces Proposed Public Offering of Common Stock
From Guardant Health, Inc.
Via Business Wire
Guardant Health Secures Coverage From Major US Commercial Health Insurers for Guardant360® Blood Test for Comprehensive Genomic Profiling
From Guardant Health, Inc.
Via Business Wire
Guardant Health Releases Inaugural ESG Report
From Guardant Health, Inc.
Via Business Wire
A New Groundbreaking Tool to Detect Colon Cancer Earlier
A novel blood test for detecting colon cancer, the third most lethal type of cancer in the US, has been created. The Colorectal Cancer Screening Blood Test can identify cancer at early stages. This... 
Via PressReach
Guardant Health Reports First Quarter 2023 Financial Results
From Guardant Health, Inc.
Via Business Wire
Guardant Health presents additional information from ECLIPSE study at 2023 Digestive Disease Week on the performance of Shield™ blood test
From Guardant Health, Inc.
Via Business Wire
Guardant Health Announces Additions to Leadership Team
From Guardant Health, Inc.
Via Business Wire
Guardant Health Announces ECLIPSE Study Update Call on May 9, 2023
From Guardant Health, Inc.
Via Business Wire
New Artificial Intelligence Tool Can Diagnose Colon Cancer
A new artificial intelligence (AI) model developed by Harvard Medical School and Taiwan’s National Cheng Kung University could provide much-needed clarity to clinicians presenting prognoses and... 
Via PressReach
Topics Artificial Intelligence Death
Guardant Health to Participate in the BofA Securities 2023 Healthcare Conference
From Guardant Health, Inc.
Via Business Wire
Guardant Health and Parker Institute for Cancer Immunotherapy (PICI) launch research collaboration to study connection between cancer biomarkers and immunotherapy treatment response
From Guardant Health, Inc.
Via Business Wire
Guardant Health announces new data to be presented at 2023 Digestive Disease Week showcasing the potential of its blood-based technology to detect colorectal cancer
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Report First Quarter 2023 Financial Results on May 9, 2023
From Guardant Health, Inc.
Via Business Wire
Guardant Health Receives Medicare Coverage for Guardant360 Response™ to Monitor Cancer Patient Response to Immunotherapy
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Present Data From 14 Studies Highlighting Advances in Precision Oncology and Cancer Screening at 2023 AACR Annual Meeting
From Guardant Health, Inc.
Via Business Wire
Guardant Health collaborates with The Ohio State University Comprehensive Cancer Center to study colorectal cancer screening adherence
From Guardant Health, Inc.
Via Business Wire
Guardant Health submits premarket approval application to the U.S. Food and Drug Administration for Shield™ blood test
From Guardant Health, Inc.
Via Business Wire
Musa Tariq Joins Guardant Health Board of Directors
From Guardant Health, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.